• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Delta 变异株的免疫逃逸能力与南非的 Beta 变异株相当。

The immune evasion ability of Delta variant is comparable to that of Beta variant in South Africa.

机构信息

Department of Applied Mathematics, Hong Kong Polytechnic University, Hong Kong, China.

Research Institute for Future Food, The Hong Kong Polytechnic University, Hong Kong, China.

出版信息

BMC Public Health. 2023 Mar 17;23(1):511. doi: 10.1186/s12889-023-15431-2.

DOI:10.1186/s12889-023-15431-2
PMID:36927400
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10020070/
Abstract

BACKGROUND

The high immune evasion ability of SARS-COV-2 Omicron variant surprised the world and appears to be far stronger than any previous variant. Previous to Omicron it has been difficult to assess and compare immune evasion ability of different variants, including the Beta and Delta variants, because of the relatively small numbers of reinfections and because of the problems in correctly identifying reinfections in the population. This has led to different claims appearing in the literature. Thus we find claims of both high and low immune evasion for the Beta variant. Some findings have suggested that the Beta variant has a higher immune evasion ability than the Delta variant in South Africa, and others that it has a lower ability.

METHOD

In this brief report, we re-analyse a unique dataset of variant-specific reinfection data and a simple model to correct for the infection attack rates of different variants.

RESULT

We find that a model with the Delta variant having  an equal or higher immune evasion ability than Beta variant is compatible with the data.

CONCLUSION

We conclude that the immune evasion ability of Beta variant is not stronger than Delta variant, and indeed, the immune evasion abilities of both variants are weak in South Africa.

摘要

背景

SARS-COV-2 奥密克戎变异株的高免疫逃逸能力令人惊讶,似乎比以往任何变异株都要强得多。在奥密克戎变异株出现之前,由于再感染的病例相对较少,以及在人群中正确识别再感染的问题,评估和比较不同变异株的免疫逃逸能力一直很困难。这导致文献中出现了不同的说法。因此,我们发现β变异株和德尔塔变异株的免疫逃逸能力都有高有低。一些研究结果表明,β变异株在南非的免疫逃逸能力高于德尔塔变异株,而另一些研究结果则表明其能力较低。

方法

在这份简短的报告中,我们重新分析了一组独特的变异特异性再感染数据和一个简单的模型,以纠正不同变异株的感染发病率。

结果

我们发现,一个假设德尔塔变异株的免疫逃逸能力与β变异株相等或更高的模型与数据是一致的。

结论

我们的结论是,β变异株的免疫逃逸能力并不强于德尔塔变异株,事实上,这两种变异株在南非的免疫逃逸能力都很弱。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4eec/10022172/7e7ae4d8e91e/12889_2023_15431_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4eec/10022172/7e7ae4d8e91e/12889_2023_15431_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4eec/10022172/7e7ae4d8e91e/12889_2023_15431_Fig1_HTML.jpg

相似文献

1
The immune evasion ability of Delta variant is comparable to that of Beta variant in South Africa.Delta 变异株的免疫逃逸能力与南非的 Beta 变异株相当。
BMC Public Health. 2023 Mar 17;23(1):511. doi: 10.1186/s12889-023-15431-2.
2
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa.南非出现奥密克戎后,SARS-CoV-2 再感染的风险增加。
Science. 2022 May 6;376(6593):eabn4947. doi: 10.1126/science.abn4947.
3
SARS CoV-2 reinfection rate is higher in the Omicron variant than in the Alpha and Delta variants.奥密克戎变异株的 SARS-CoV-2 再感染率高于阿尔法和德尔塔变异株。
Ir J Med Sci. 2023 Apr;192(2):751-756. doi: 10.1007/s11845-022-03060-4. Epub 2022 Jun 17.
4
Reduction in the infection fatality rate of Omicron variant compared with previous variants in South Africa.与南非先前的变异株相比,奥密克戎变异株的感染病死率降低。
Int J Infect Dis. 2022 Jul;120:146-149. doi: 10.1016/j.ijid.2022.04.029. Epub 2022 Apr 21.
5
Omicron SARS-CoV-2 variant of concern: A review on its transmissibility, immune evasion, reinfection, and severity.关注的奥密克戎 SARS-CoV-2 变体:对其传染性、免疫逃逸、再感染和严重性的综述。
Medicine (Baltimore). 2022 May 13;101(19):e29165. doi: 10.1097/MD.0000000000029165.
6
Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review.奥密克戎(B.1.1.529)-关注变异株-分子特征和流行病学:简要综述。
Eur Rev Med Pharmacol Sci. 2021 Dec;25(24):8019-8022. doi: 10.26355/eurrev_202112_27653.
7
The Spread of SARS-CoV-2 Variant Omicron with a Doubling Time of 2.0-3.3 Days Can Be Explained by Immune Evasion.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变异株奥密克戎以2.0至3.3天的倍增时间传播可由免疫逃逸来解释。
Viruses. 2022 Jan 30;14(2):294. doi: 10.3390/v14020294.
8
Omicron: the highly mutational COVID-19 variant with immune escape.奥密克戎:具有免疫逃逸能力的高度突变型 COVID-19 变体。
Pan Afr Med J. 2022 Jan 31;41:84. doi: 10.11604/pamj.2022.41.84.33373. eCollection 2022.
9
A simple model to estimate the transmissibility of the Beta, Delta, and Omicron variants of SARS-COV-2 in South Africa.一种简单的模型,用于估计 SARS-COV-2 的 Beta、Delta 和 Omicron 变体在南非的传播能力。
Math Biosci Eng. 2022 Jul 22;19(10):10361-10373. doi: 10.3934/mbe.2022485.
10
COVID-19 pandemic dynamics in South Africa and epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron).南非的 COVID-19 疫情动态及三种关注变异株(Beta、Delta 和 Omicron)的流行病学特征。
Elife. 2022 Aug 9;11:e78933. doi: 10.7554/eLife.78933.

引用本文的文献

1
Assessing the dynamics and impact of COVID-19 vaccination on disease spread: A data-driven approach.评估新冠疫苗接种对疾病传播的动态变化及影响:一种数据驱动的方法。
Infect Dis Model. 2024 Mar 12;9(2):527-556. doi: 10.1016/j.idm.2024.02.010. eCollection 2024 Jun.
2
Prediction of the next major outbreak of COVID-19 in Mainland China and a vaccination strategy for it.中国大陆下一次新冠疫情大爆发的预测及其疫苗接种策略。
R Soc Open Sci. 2023 Aug 30;10(8):230655. doi: 10.1098/rsos.230655. eCollection 2023 Aug.

本文引用的文献

1
Resolving the enigma of Iquitos and Manaus: A modeling analysis of multiple COVID-19 epidemic waves in two Amazonian cities.解析伊基托斯和马瑙斯的奥秘:对两个亚马孙城市中 COVID-19 多次疫情浪潮的建模分析。
Proc Natl Acad Sci U S A. 2023 Mar 7;120(10):e2211422120. doi: 10.1073/pnas.2211422120. Epub 2023 Feb 27.
2
COVID-19 pandemic dynamics in South Africa and epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron).南非的 COVID-19 疫情动态及三种关注变异株(Beta、Delta 和 Omicron)的流行病学特征。
Elife. 2022 Aug 9;11:e78933. doi: 10.7554/eLife.78933.
3
Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2.
保护和衰减对 SARS-CoV-2 的天然和混合免疫。
N Engl J Med. 2022 Jun 9;386(23):2201-2212. doi: 10.1056/NEJMoa2118946. Epub 2022 May 25.
4
SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21.2020 - 2021年南非农村和城市地区严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的发病率、传播及再感染情况:PHIRST-C队列研究结果
Lancet Infect Dis. 2022 Jun;22(6):821-834. doi: 10.1016/S1473-3099(22)00069-X. Epub 2022 Mar 14.
5
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa.南非出现奥密克戎后,SARS-CoV-2 再感染的风险增加。
Science. 2022 May 6;376(6593):eabn4947. doi: 10.1126/science.abn4947.
6
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection.新冠病毒疫苗接种和既往感染后对 SARS-CoV-2 的保护作用。
N Engl J Med. 2022 Mar 31;386(13):1207-1220. doi: 10.1056/NEJMoa2118691. Epub 2022 Feb 16.
7
Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant.自然免疫对SARS-CoV-2贝塔变异株再感染的效力
N Engl J Med. 2021 Dec 30;385(27):2585-2586. doi: 10.1056/NEJMc2110300. Epub 2021 Dec 15.
8
Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India.印度德里地区一种新型 SARS-CoV-2 变体的基因组特征和流行病学研究。
Science. 2021 Nov 19;374(6570):995-999. doi: 10.1126/science.abj9932. Epub 2021 Oct 14.
9
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.NVX-CoV2373 新冠疫苗对 B.1.351 变异株的有效性。
N Engl J Med. 2021 May 20;384(20):1899-1909. doi: 10.1056/NEJMoa2103055. Epub 2021 May 5.
10
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.科维希尔德腺病毒载体新冠疫苗(ChAdOx1 nCoV-19)对 B.1.351 变异株的有效性。
N Engl J Med. 2021 May 20;384(20):1885-1898. doi: 10.1056/NEJMoa2102214. Epub 2021 Mar 16.